Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.

ABSTRACT:

Purpose

Novel pharmaceutical treatments reducing cardiovascular events in dyslipidaemia patients must demonstrate clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers.

Objective

To assess the cost-effectiveness of statin monotherapy compared to additive lipid-lowering therapies for primary and secondary cardiovascular prevention from the perspective of Germany's healthcare system.

Methods

Transition probabilities and hazard ratios were derived from cardiovascular outcome trials for statin combinations with icosapent ethyl (REDUCE-IT), evolocumab (FOURIER), alirocumab (ODYSSEY), ezetimibe (IMPROVE-IT), and fibrate (ACCORD). Costs and utilities were retrieved from previous literature. The incidence of major adverse

SUBMITTER: Michaeli DT 

PROVIDER: S-EPMC10397126 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature